(Q34425422)

2 August 2017

1 reference

title

Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis (English)

1 reference

2 August 2017

1 reference

Domenic A Sica

1

1 reference

2 August 2017

1 January 2005

1 reference

2 August 2017

Heart Failure Reviews

1 reference

2 August 2017

10

1 reference

2 August 2017

23-29

1 reference

2 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s10741-005-2345-1

2 August 2017

0 references

cites work

Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10741-005-2345-1

Hydrochlorothiazide and spironolactone in hypertension

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10741-005-2345-1

Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data

21 January 2018

1 reference

12 December 2020

Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans

1 reference

12 December 2020

How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

1 reference

12 December 2020

Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program

1 reference

12 December 2020

Eplerenone: cardiovascular protection

1 reference

12 December 2020

Interactions of aldosterone antagonist diuretics with human serum proteins

1 reference

12 December 2020

Aldosterone and aldosterone antagonism in systemic hypertension

1 reference

12 December 2020

Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients

1 reference

12 December 2020

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

12 December 2020

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

1 reference

12 December 2020

Aldosterone-receptor antagonism and end-stage renal disease

1 reference

12 December 2020

Influence of food on the bioavailability of spironolactone

1 reference

12 December 2020

Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment

1 reference

12 December 2020

Efficacy of low-dose spironolactone in subjects with resistant hypertension

1 reference

12 December 2020

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

12 December 2020

1 reference

12 December 2020

Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade

1 reference

12 December 2020

Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5.

1 reference

12 December 2020

Aldosterone receptor antagonists for hypertension: what do they offer?

1 reference

12 December 2020

Spironolactone: a re-examination

1 reference

12 December 2020

Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours

1 reference

12 December 2020

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

1 reference

12 December 2020

Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).

1 reference

12 December 2020

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

1 reference

12 December 2020

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

12 December 2020

The 45-year story of the development of an anti-aldosterone more specific than spironolactone

1 reference

12 December 2020

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

1 reference

12 December 2020

Aldosterone antagonists in hypertension and heart failure

1 reference

12 December 2020

Indications for Hospitalization of Patients With Hyperkalemia

1 reference

12 December 2020

Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety

1 reference

12 December 2020

Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites

1 reference

12 December 2020

Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure

1 reference

12 December 2020

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

1 reference

12 December 2020

Spironolactone: Disposition, Metabolism, Pharmacodynamics, and Bioavailability

1 reference

12 December 2020

Prolonged alteration of renin responsiveness after spironolactone therapy. A cause of false-negative testing for low-renin hypertension.

1 reference

12 December 2020

Experience with the Use of an Aldosterone Antagonist in Selected Hypertensive Patients

1 reference

12 December 2020

The evolution of aldosterone antagonists

1 reference

12 December 2020

10.1007/S10741-005-2345-1

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

15947888